Connect your AI

Revolution Medicines, Inc. RVMD Q4 2024 Annual earnings

Reported February 26, 2025 · After market close

Revenue$261.6MBeat by $261.2M Diluted EPS-$1.12Miss by $0.11

Revenue estimate$346.2K

EPS estimate-$1.01

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$17.8M

EPS estimate-$1.96

Financials

Q4 2024

Income statement

Revenue--100%

Operating income-$216.3M-20.2%

Net income-$194.6M-20.4%

EPS (diluted)-$1.13+6.6%

Balance sheet

Cash & equivalents$543.1M-22.0%

Total debt$135.8M+54.5%

Total equity$2.3B+24.0%

Total assets$2.6B+24.1%

Cash flow

Operating cash flow-$138.3M-14.7%

CapEx$1.2M-47.3%

Free cash flow-$139.5M-13.5%

Valuation & ratios

Valuation

as of 12/31/24

Market cap$8.08B+99.6%

Enterprise value$7.68B+123%

Returns & leverage

Return on equity-29.3%-4.0pp

Debt / equity0.1×0.0×

Current ratio14.2×+1.1×

Versus estimates

Revenue

Q4 2024$261.6MBeat by $261.2M

Diluted EPS

Q1 2026-$2.29Miss by $0.46 Q4 2025-$1.86Miss by $0.28 Q3 2025-$1.61Miss by $0.19 Q2 2025-$1.31Miss by $0.37 Q1 2025-$1.13Miss by $0.01

Q4 2024-$1.12Miss by $0.11

Ask the moment Revolution Medicines, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Revolution Medicines, Inc. report Q4 2024 earnings?: Revolution Medicines, Inc. (RVMD) reported Q4 2024 earnings on February 26, 2025 after market close.
What were Revolution Medicines, Inc.'s Q4 2024 revenue and EPS?: Revolution Medicines, Inc. reported revenue of $261.6M and diluted EPS of $-1.12 for Q4 2024.
Did Revolution Medicines, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $346.2K by $261.2M. EPS missed the consensus estimate of $-1.01 by $0.11.
Where can I find Revolution Medicines, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-027736) directly on SEC EDGAR. The filing index links above go to sec.gov.